NeuroSense Therapeutics (NASDAQ:NRSN) Stock Rating Cut to Hold at Roth Capital

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by Roth Capital from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks reports.

A number of other brokerages have also weighed in on NRSN. HC Wainwright initiated coverage on shares of NeuroSense Therapeutics in a report on Thursday, September 3rd. They set a “buy” rating for the company. Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $170.00.

NeuroSense Therapeutics Trading Up 0.3%

NASDAQ NRSN opened at $3.49 on Monday. The company’s 50-day moving average price is $7.15 and its 200-day moving average price is $12.11. The stock has a market cap of $6.63 million, a PE ratio of -0.32 and a beta of 1.66. NeuroSense Therapeutics has a 12 month low of $3.28 and a 12 month high of $26.64.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned 0.21% of NeuroSense Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapeutic approaches intended to address multiple disease mechanisms, including neuroinflammation, abnormal RNA regulation and other biological processes associated with the progression of neurological disorders.

Its leading product candidate is PrimeC, an oral combination formulation of ciprofloxacin and celecoxib being developed primarily for amyotrophic lateral sclerosis (ALS).